Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab plus AG in advanced pancreatic cancer
NCT06916975Phase 2Not yet recruiting
- Start
- Apr 2025
- Primary completion
- Dec 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in pancreatic cancer (PC). Primary endpoint: Objective Response Rate up to 20 weeks. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06916975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06916975.